![Phenol, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis-](https://static.cymitquimica.com/cas-image/30097-phenol-33-5-fluoro-24-pyrimidinediyl-diimino-bis.png)
CAS: 575474-82-7 - Phenol, 3,3'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis-
Formula:C16H13FN4O2
- Synonyms:
- R112
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | R 112 (pharMaceutical) REF: IN-DA00ECEICAS: 575474-82-7 | % | 67.00 €~284.00 € | Mon 16 Dec 24 |
 | R112 REF: TM-T3185CAS: 575474-82-7 | 99.06% - 99.84% | 39.00 €~1,008.00 € | Mon 23 Dec 24 |
 | R 112 REF: TR-R060010CAS: 575474-82-7 | - - - | 1,063.00 € | Tue 28 Jan 25 |
 | R 112 REF: 3D-AYA47482CAS: 575474-82-7 | Min. 95% | 189.00 €~814.00 € | Mon 27 Jan 25 |
R 112 (pharMaceutical)
CAS:575474-82-7
Formula:
C16H13FN4O2
Purity:
%
Color and Shape:
Solid
Molecular weight:
312.2984
Ref: IN-DA00ECEI
| 10mg | 67.00 € | ||
| 50mg | 145.00 € | ||
| 100mg | 157.00 € | ||
| 250mg | 284.00 € |
Estimated delivery in United States, on Monday 16 Dec 2024
R112
CAS:575474-82-7
R112 ((E)-Elafibranor) is an ATP-competitive inhibitor of Syk kinase.
Formula:
C16H13FN4O2
Purity:
99.06% - 99.84%
Color and Shape:
Solid
Molecular weight:
312.3
Ref: TM-T3185
| 1mg | 39.00 € | ||
| 2mg | 52.00 € | ||
| 5mg | 84.00 € | ||
| 10mg | 125.00 € | ||
| 25mg | 219.00 € | ||
| 50mg | 330.00 € | ||
| 100mg | 489.00 € | ||
| 500mg | 1,008.00 € | ||
| 1mL*10mM (DMSO) | 93.00 € |
Estimated delivery in United States, on Monday 23 Dec 2024
R 112
Controlled ProductCAS:575474-82-7
Formula:
C16H13FN4O2
Color and Shape:
Neat
Molecular weight:
312.298
Ref: TR-R060010
| 250mg | 1,063.00 € |
Estimated delivery in United States, on Tuesday 28 Jan 2025
R 112
CAS:575474-82-7
R 112 is a recombinant virus that has been genetically modified to express a viral …
Formula:
C16H13FN4O2
Purity:
Min. 95%
Molecular weight:
312.3 g/mol
Ref: 3D-AYA47482
| 1mg | 189.00 € | ||
| 2mg | 307.00 € | ||
| 5mg | 400.00 € | ||
| 10mg | 569.00 € | ||
| 25mg | 814.00 € |
Estimated delivery in United States, on Monday 27 Jan 2025
